PET scan using GLP-1 receptor tracer for cancers
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial uses a special PET scan (a 3D imaging test) to look for cancer cells that have GLP-1 receptors, a protein on some tumors. It aims to see if this scan can help find or monitor cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have suspected, newly diagnosed, or previously treated cancer (confirmed by MRI, CT, tumor markers, or biopsy).
- You are scheduled to have a Exendin 4 PET/CT scan.
- You (or a parent/legal guardian) can give informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special PET scan to see how well it can find and track different types of cancer. It may help doctors better understand your cancer.
This trial tests a new type of PET/CT scan that uses a special tracer (called ⁶⁸Ga-FXX489) to help find and diagnose cancers. It is for people who are strongly suspected to have cancer and want to see if this new imaging method can help their doctors learn more about their disease.
This trial uses a special PET scan called 68Ga-NK224 to look for a protein called PD-L1 in tumors. This may help doctors understand your cancer better and find the right treatment for you.
This study uses a special PET scan to measure how well insulin-producing cells (“beta cells”) in the pancreas are working in people with diabetes. It’s meant to help researchers understand diabetes biology and test whether the scan can reflect beta cell function.
This trial tests a special PET/CT scan using a new tracer (68Ga-FAPI) to help show tumors in the pancreas, bile ducts, stomach, or certain ovarian cancers. It may help doctors better see where cancer is in preparation for surgery or biopsy.
This trial tests a new PET/CT scan using a special tracer to detect cancer that has spread to the lining of the abdomen (peritoneal carcinomatosis) in people with colorectal, stomach, ovarian, or pancreatic cancer. It aims to see if this scan is better at finding the spread than standard imaging.
Hear when a new GLP1-R-related Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.